Connection

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Search Results to Maurizio Zangari

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Zangari, Maurizio

One or more keywords matched the following properties of Zangari, Maurizio

Property

Value

overview

Maurizio Zangari, M.D. is a Professor of Medicine with the Myeloma Institute for Research and Therapy at UAMS. Dr. Zangari trained as a fellow in Bone Marrow Transplant and Hematology at Mount Sinai Hospital in New York and a resident in Internal Medicine at Wykoff Heights Medical Center, also in New York. He earned is MD from the University of Padua in Italy. Dr. Zangari was previously at the Myeloma Center from 1998-2007, then left for the University of Utah from 2007-2013. He rejoined the Myeloma Center in 2013 and continues to be greatly involved with clinical trials and research. He is an internationally recognized expert in multiple myeloma with an extensive bibliography of peer-reviewed articles and invited presentations. Dr. Zangari is board certified in Hematology and Internal Medicine. He is a member of the American Society of Hematology.

research overview

Hypercoagulability in Cancer Patients. The role of activated protein C in thrombotic manifestation of patients with multiple myeloma. Since the start at the University of Utah I have initiated retrospective and prospective studies of the protein C system function in patients with paraproteinemias and myeloproliferative disorder. I have also continued to test the effect of proteosome inhibition on platelet function. After establishing 5GTM1 C57BL/KaLwRij sub-strain in a pre-clinical model I have tested the function of a proteasome inhibitor through the PTH-PTHR axis. In the last 22 months I focused the research to confirm the hypothesis of the PTH essential role in anti-myeloma proteasome activity testing the effect of PTHR antibodies and the effects of parathyroidectomy. The C57 BLACK MOUSE MODEL will be measured in the presence of different proteasome inhibitors MLN 9708, carfilzomib and CEP 18770. I am the principal investigator in three open investigator-initiated trials (Phase I Exploratory Study of Panobinostat IV in Combination with Relapsed/Refractory Multiple Myeloma Patients; Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients; Bone Effect of Bortezomib in Patients with relapsed/refractory Multiple Myeloma), which focus on the bone anabolic activity of proteasome inhibition to determine the minimal proteosome inhibition associated with the anabolic bone effect in multiple myeloma and to evaluate the effect of proteasome inhibition in smoldering myeloma patients. A phase I study, a combination of two bone anabolic drugs panabinostat (a histone deacetylase inhibitor HDAC) and bortezomib in relapse/refractory multiple myeloma patients.

One or more keywords matched the following items that are connected to Zangari, Maurizio

Item Type	Name
Academic Article	Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Academic Article	MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
Academic Article	Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.
Academic Article	DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
Academic Article	The blood coagulation mechanism in multiple myeloma.
Academic Article	High-dose therapy and immunomodulatory drugs in multiple myeloma.
Academic Article	Treatment of multiple myeloma.
Academic Article	Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Academic Article	Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Academic Article	Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
Academic Article	Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
Academic Article	Infection--an underappreciated cause of bone pain in multiple myeloma.
Academic Article	Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.
Academic Article	Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Academic Article	Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Academic Article	High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Academic Article	Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
Academic Article	Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Academic Article	Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma.
Academic Article	Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Academic Article	Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Academic Article	High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Academic Article	Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Academic Article	Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Academic Article	Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Academic Article	Immunomodulatory drugs in multiple myeloma.
Academic Article	Hyperammonemia and encephalopathy in patients with multiple myeloma.
Academic Article	Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Academic Article	Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Academic Article	Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Academic Article	Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.
Academic Article	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Academic Article	A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Academic Article	Response to bortezomib and activation of osteoblasts in multiple myeloma.
Academic Article	Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma.
Academic Article	Thrombosis in multiple myeloma.
Academic Article	Effect of time to infusion of autologous stem cells (24 vs. 48?h) after high-dose melphalan in patients with multiple myeloma.
Academic Article	Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Academic Article	The molecular classification of multiple myeloma.
Academic Article	Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
Academic Article	Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Academic Article	Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Academic Article	Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Academic Article	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Academic Article	Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders.
Academic Article	NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.
Academic Article	Multiple myeloma presenting as CEA-producing rectal cancer.
Academic Article	Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.
Academic Article	Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma.
Academic Article	The Arkansas approach to therapy of patients with multiple myeloma.
Academic Article	Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs.
Academic Article	Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
Academic Article	Low-risk identification in multiple myeloma using a new 14-gene model.
Academic Article	A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
Academic Article	Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
Academic Article	Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Academic Article	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Academic Article	A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.
Academic Article	Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
Academic Article	Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Academic Article	Anticoagulation regimens for thalidomide and lenalidomide.
Academic Article	Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Academic Article	Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Academic Article	Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
Academic Article	Impact of bortezomib on bone health in myeloma: a review of current evidence.
Academic Article	Clinical and biological features of multiple myeloma involving the gastrointestinal system.
Academic Article	Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
Academic Article	The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Academic Article	RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.
Academic Article	Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Academic Article	Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
Academic Article	Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.
Academic Article	High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Academic Article	Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
Academic Article	Estimation of daily proteinuria in patients with multiple myeloma by using the protein-to-creatinine ratio in random urine samples.
Academic Article	Bone and paraproteinemias.
Concept	Multiple Myeloma
Academic Article	Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
Academic Article	Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Academic Article	A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.
Academic Article	Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
Academic Article	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Academic Article	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Academic Article	The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
Academic Article	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Academic Article	Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.
Academic Article	Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.
Academic Article	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.
Academic Article	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.
Academic Article	The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.
Academic Article	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Academic Article	Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
Academic Article	Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo.
Academic Article	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
Academic Article	Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.
Academic Article	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.
Academic Article	The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.
Academic Article	Kinase domain activation through gene rearrangement in multiple myeloma.
Academic Article	Visualizing collagen proteolysis by peptide hybridization: From 3D cell culture to in vivo imaging.
Academic Article	FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients.
Academic Article	Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Academic Article	Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Grant	UARK 2002-37, An Open Label Phase II Extension Study to Assess the Long-Term Safety and Tolerability of MRA Given to Patients with Multiple Myeloma
Academic Article	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
Academic Article	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome.
Academic Article	A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma.
Academic Article	Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Academic Article	Long-term outcomes after autologous stem cell transplantation for multiple myeloma.
Academic Article	BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Academic Article	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.
Academic Article	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Academic Article	Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Academic Article	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Academic Article	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Academic Article	Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience.
Academic Article	PHF19 inhibition as a therapeutic target in multiple myeloma.
Academic Article	Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma.
Academic Article	High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse.
Academic Article	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Academic Article	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Academic Article	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma.
Academic Article	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
Academic Article	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Academic Article	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Academic Article	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.
Academic Article	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Academic Article	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Academic Article	Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions.
Academic Article	CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Academic Article	Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
Academic Article	The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
Academic Article	Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Academic Article	Variability of definition of high-risk multiple myeloma across phase III clinical trials.
Academic Article	Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Academic Article	Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma.
Academic Article	Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Academic Article	Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Academic Article	Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
Academic Article	A gene signature can predict risk of MGUS progressing to multiple myeloma.
Academic Article	Growth and dormancy control of myeloma cells by mesenchymal stem cells.
Academic Article	Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines.
Academic Article	The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Academic Article	BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
Academic Article	High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma.
Academic Article	Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.
Academic Article	Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Academic Article	Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Academic Article	Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Academic Article	Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.
Academic Article	Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Academic Article	CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients.

Search Criteria

Multiple Myeloma